1 / 30

REG in COPD

REG in COPD. Marc Miravitlles Pneumology Department. Hospital Universitari Vall d ’ Hebron. Barcelona, Spain. (marcm@separ.es). Diagnosis of respiratory symptoms in general population. Respondents 6,758. No respiratory symptoms 4,314 (64%). Respiratory symptoms 2,444 (36%).

studs
Download Presentation

REG in COPD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. REG in COPD Marc Miravitlles Pneumology Department. Hospital Universitari Vall d’Hebron. Barcelona, Spain. (marcm@separ.es)

  2. Diagnosis of respiratory symptoms in general population Respondents6,758 No respiratory symptoms4,314 (64%) Respiratory symptoms2,444 (36%) Did not consult physician1,073 (44%) Consult physician1,371 (56%) No spirometry786 (57.4%) Spirometry585 (42.6%) Miravitlles et al. Respir Med 2006; 100: 1973-1980

  3. Knowledge of COPD % Survey in 6,758 subjects >40 years. Up to 24% reported having at least one chronic respiratory symptom Miravitlles et al. Respir Med 2006; 100: 1973-1980

  4. Spirometry in Primary Care Miravitlles et al. Arch Bronconeumol 2000; 36: 500-5

  5. COPD-6 (FEV1/FEV6) Represas et al. Arch Bronconeumol 2010; 46: 426-432

  6. Questionnaires and COPD Martinez et al. COPD 2008; 5: 85-95

  7. Questionnaires and COPD Cut-off: 4 units Sensibility: 93.6% Specificity: 64.8% PPV: 69.5% NPV: 92.2% Classified: 78.1% Miravitlles et al. Med Clin 2012; 139: 522-530

  8. Venn diagram of COPD The large rectangle represents the full study group. The clear circles represent the proportion of subjects with COPD (FEV1/FVC < 70%). Adults older than 50 years in New Zealand (n= 469) Marsh et al. Thorax 2008; 63: 761-767

  9. Han et al. Lancet Infect Dis 2012; online

  10. Clasificación GOLD Han et al. Lancet Infect Dis 2012; online

  11. Clasificación GOLD Lange et al. AJRCCM 2012; 186: 975-981

  12. Soriano et al. Chest 2012; online first

  13. Clasificación GOLD Mortalidad a los 10 años de seguimiento en pacientes GOLD D Soriano et al. Chest 2012; online first

  14. Clasificación GOLD Soriano et al. Chest 2012; online first

  15. Phenotype diagnosis Step 2 Overlap COPD-asthmaphenotype Phenotype characterisation (C) (D) Exacerbator phenotype(2 or more ex/yr) (B) No exacerbations< 2 ex/yr Emphysema phenotype Chronic bronchitisphenotype (A) Miravitlles et al. Arch Bronconeumol 2012; 48: 247-257

  16. Phenotypes of COPD AJRCCM 2010; 182: 598-604

  17. Br J Gen Pract 2012: DOI:10.3399

  18. Phenotypes of COPD Unpublished

  19. Phenotypes of COPD Unpublished

  20. Phenotype-guided treatment CEx. with emphysema DEx. with CB BOverlap ANo exacerbator Bronchodilators ICS Muc/NAC Roflumilast Antibiotics Miravitlles et al. ERJ 2012; online

  21. Costs of COPD €/year Miravitlles et al. Chest 2003; 123: 784-791

  22. Costs of COPD Drugs Visits and diagnostic tests 16 42 42 Hospital costs Miravitlles et al. Chest 2003; 123: 784-791

  23. Costs of treatment of COPD Miravitlles et al. Respir Med 2009;103:714-721

  24. Thorax 2013;68:4-6 BMJ 2012;345: e7390

  25. SIDIAP Bolivar et al. Med Clin 2012; 138: 617-621

  26. SIDIAP Bolivar et al. Med Clin 2012; 138: 617-621

  27. REG in COPD • Diagnosis of COPD in Primary Care. • Validation of guidelines • Compliance with guidelines. • Cost of illness, cost-effectiveness • Validation of phenotypes • Safety of treatments.

More Related